---
symbol: "JP225"
name: "Nikkei 225"
date: 2026-08-21
change_pct: 1.222535038864068
direction: "up"
event_type: "product_launch"
url: "https://perplo.app/why/JP225/2026-08-21"
updated_at: 2026-08-21T13:06:45.670Z
---

# Why Nikkei 225 (JP225) rose 1.22% on August 21, 2026

Nikkei 225 (JP225) rose 1.22% on August 21, 2026 — Celltrion Japan autoimmune launch boosts Nikkei.

## What happened

Celltrion, a Korean biopharma, launched SteQeyma IV (a copycat autoimmune drug) in Japan, marking an expansion of its local presence and signaling a new product revenue stream in the region.

## Why it moved

A successful Japan pharma launch lifts sentiment around Korean healthcare export competitiveness and bilateral trade momentum, supporting the Nikkei as a regional bellwether; this adds marginal tailwind to the Japan…

## Why it matters

The Japan (Yen & Equities) theme is currently caught in BoJ tightening — today's move reflects modest equity strength overcoming carry-unwind headwinds, with Celltrion's Japan expansion adding positive trade-flow…

## What would break the thesis

If SteQeyma IV uptake stalls due to reimbursement delays or clinical headwinds, or if broader Japan export momentum cools, the pharma trade narrative weakens and the Nikkei loses this support.

## Sources

- [Celltrion expands Japan push with SteQeyma IV launch](https://www.koreaherald.com/article/10848116) — Korea Herald
- [Flash PMI shows Japan factories leading strongest growth since February](https://investinglive.com/news/flash-pmi-shows-japan-factories-leading-strongest-growth-since-february/) — ForexLive
- [Japan exports beat estimates in July as robust chip shipments power fifth straight month of gains](https://www.cnbc.com/2026/08/20/japan-exports-imports-july-chip-ai.html) — CNBC

---

Trade JP225 perpetual futures 24/7 onchain: https://perplo.app/asset/JP225